Dual-Target CAR T Therapy Shows Promise in Resistant Myeloma

Mass General Brigham

A first-in-human study by Mass General Brigham Cancer Institute investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. TriPRIL — short for trimeric APRIL (a proliferation-inducing ligand) — recognizes two proteins on myeloma cells instead of just one. Researchers published their findings in The Lancet.

Multiple myeloma is a cancer of plasma cells, which are immune cells that make antibodies. To create CAR T-cell therapy, scientists modify a patient's T cells so they can find and attack myeloma cells. Existing CAR T-cell therapies recognize B-cell maturation antigen (BCMA) on myeloma cells. TriPRIL was engineered by Mass General Brigham researchers to make the CAR-T cells recognize both BCMA and a second protein, transmembrane activator and CAML interactor (TACI). Because the treatment is based on human proteins, the researchers believe it may be less likely to lead to anti-drug antibodies that can reduce the long-term persistence and effects of other CAR-T cells.

"BCMA-targeted CAR T-cell therapy has transformed multiple myeloma treatment, but most patients eventually relapse," said co-senior author Marcela V. Maus, MD, PhD, director of the Mass General Brigham Cancer Institute's Cellular Immunotherapy Program. "TriPRIL adds TACI as a second target, allowing it to find and attack myeloma cells, even if they stop expressing BCMA."

The phase 1 TriPRIL trial treated 15 patients at the Mass General Brigham Cancer Institute whose multiple myeloma had come back despite many treatments. Nine patients had previously received BCMA-directed CAR T-cell therapy but saw their cancer progress. Twelve of the fifteen patients (80%) responded, meaning cancer signs fell by at least half. In eight (53%), blood, urine and bone marrow tests found no signs of active myeloma.

TriPRIL cells remained detectable in some patients' blood beyond six months after treatment. The treatment was also relatively safe, with no severe cases of cytokine release syndrome or neurotoxicity.

"Seeing this new treatment work in patients whose cancer had returned after treatment targeting BCMA stood out," Maus said. "It was also encouraging that the patients we tested showed no immune reaction against TriPRIL.

Because the study included only 15 patients and followed them for a relatively short time, researchers need larger, longer studies to determine how long the benefits last and identify less common side effects. They are planning a phase 2 trial with more patients and longer follow-up.

Authorship: In addition to Maus, Mass General Brigham authors include Benjamin R. Puliafito, Charlotte E. Graham, Noopur S. Raje, Andrew J. Yee, Diana D. Cirstea, Andrew R. Branagan, Nora K. Horick, Aiyana L. Parker, Maxx King, Marisa G. Ogier, Mark B. Leick, Kathleen M.E. Gallagher, and Matthew J. Frigault. Additional authors include Sarah Nikiforow and members of the TriPRIL Working Group.

Disclosures: Maus is an inventor on patents related to this study and adoptive cell therapies held by Massachusetts General Hospital and the University of Pennsylvania, some of which are licensed to biotechnology companies. She receives research support from BMS, Kite Pharma and Sobi; serves as a consultant to multiple cell therapy companies; holds equity in A2Bio, Altido Therapeutics, Caronilex and Umoja; and serves on the board of directors of Umoja. Additional author disclosures can be found in the paper.

Funding: This research was funded by internal Mass General Brigham funding. Additional support for correlative studies was provided by the V Foundation.

Paper cited: Puliafito BR et al. "Trimeric APRIL (TriPRIL) CAR T-cell therapy for relapsed or refractory multiple myeloma: A first-in-human phase 1 trial using a dual-targeted, ligand-based CAR," The Lancet.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.